Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline

Januzzi, J. et al. (2019) Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. European Journal of Heart Failure, 21(3), pp. 386-388. (doi: 10.1002/ejhf.1419) (PMID:30767353)

Abstract

No abstract available.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Petrie, Professor Mark and Ferreira, Mr Joao Pedro
• Authors: Januzzi, J., Ferreira, J. P., Böhm, M., Kaul, S., Wanner, C., Brueckmann, M., Petrie, M., Ofstad, A.-P., Zeller, C., George, J., Fitchett, D., and Zannad, F.
• College/School: College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
• Journal Name: European Journal of Heart Failure
• Publisher: Wiley
• ISSN: 1388-9842
• ISSN (Online): 1879-0844
• Published Online: 14 February 2019
• Copyright Holders: Copyright © 2019 The Authors
• First Published: First published in European Journal of Heart Failure 21(3):386-388
• Publisher Policy: Reproduced in accordance with the copyright policy of the publisher